Applicant, as named in the Orange Book

Eisai Inc

Part of Eisai

Company and ticker: cliffwatch mapping, checked against SEC EDGAR

Next listed expiry: Halaven on 8 Jul 2027. 3 products with live protection, 4 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Halaven NDA 201532 eribulin mesylate	eribulin mesylate	8 Jul 2027 patent	patent
Dayvigo NDA 212028 · 2 strengths lemborexant	lemborexant	21 Oct 2035 patent	patent
Lenvima NDA 206947 · 2 strengths lenvatinib mesylate	lenvatinib mesylate	15 Nov 2038 patent	patent

Recent events

Halaven · Generic approved · ANDA 218930, KindosApproved 19 Oct 2026Detected 25 Oct 2026
Halaven · Generic approved · ANDA 217085, NatcoApproved 1 Jun 2026Detected 25 Oct 2026
Halaven · Generic approved · ANDA 219054, Xgen PharmsApproved 16 Mar 2026Detected 25 Oct 2026
Halaven · Enters 12-month window basis: patentListed date 8 Jul 2027Detected 24 Oct 2026

Products without listed protection (4)

Drug	Ingredient	Earliest generic entry	Basis
Aricept NDA 022568 donepezil hydrochloride	donepezil hydrochloride	open now no listed protection	no listed protection
Aricept NDA 020690 · 2 strengths donepezil hydrochloride	donepezil hydrochloride	open now no listed protection	no listed protection
Banzel NDA 201367 rufinamide	rufinamide	open now no listed protection	no listed protection
Banzel NDA 021911 · 2 strengths rufinamide	rufinamide	open now no listed protection	no listed protection